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Enduring diabetes increases the probability of developing secondary damage to numerous systems, and these complications
represent a cause of morbidity and mortality. Establishing the causes of diabetes remains the key step to eradicate the disease,
but prevention as well as finding therapies to ameliorate some of the major diabetic complications is an equally important step
to increase life expectancy and quality for the millions of individuals already affected by the disease or who are likely to develop
it before cures become routinely available. In this review, we will firstly summarize some of the major complications of diabetes,
including endothelial and pancreatic islets dysfunction, retinopathy, and nephropathy, and then discuss the emerging roles exerted
by the neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) to counteract these ranges of pathologies that are
precipitated by the prolonged hyperglycemic state. Finally, we will describe the main signalling routes activated by the peptide and
propose possible future directions to focus on developing more effective peptide-based therapies to treat the major complications
associated with longstanding diabetes.
1. Introduction
The prevalence of diabetes is increasing worldwide. Accord-
ing to the World Health Organization (WHO), the total
number of people affected by diabetes is expected to rise
to an estimated 300 million cases by the year 2025 [1].
The onset of diabetes immediately increases the possibility
for the patient to develop a broad spectrum of irreversible
complications [2]. Both type 1 [3] and type 2 [4] diabetes
have devastating consequences especially on small and large
blood vessels. A considerable effort has been put into finding
treatments for this condition and its complications. Among
them, targeting endogenous peptidergic systems or their
downstream signallingmechanisms is emerging as a valuable
therapeutic option.
In this review we will outline some of the most recent
advances from our research group and others in relationship
to the role of a promising neuropeptide candidate endowed
with potential beneficial effects to treat or ameliorate certain
aspects of diabetes, namely, the pituitary adenylate cyclase-
activating polypeptide (PACAP). We will emphasize how
the neuropeptide interferes and in some cases prevents
the development of specific pathological consequences of
the disease, such as micro- and macroangiopathy, retinal
dysfunction, and defective pancreatic𝛽-cell insulin secretion,
and discuss themajor intracellular events implicated and how
these are hampered by peptide treatment. The final purpose
will be to shed more light into PACAP function for future
exploitation in therapies aimed at arresting or preventing
the development of complications associated with disease
progression.
2. Diabetes and Its Complications
The term diabetes mellitus indicates a group of metabolic
disorders characterized by high blood sugar and impaired
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They are distinctive phenotypes found in both types of diabetes, which are responsible for the high
incidence of stroke, heart attack, and organ damage in diabetic patients.
Pancreatic islets dysfunction
It is a progressive dysfunction of pancreatic islet alpha and beta cells, caused either by cell death or
dedifferentiation in immature fetal or neonatal-like state with impaired glucose-stimulated insulin
secretion which results in inadequate control of hyperglycemia.
Diabetic retinopathy (DR)
It damages the small blood vessels that serve the retina, with loss of visual ability. Further morbidity
states associated with DR and diabetes are the increased probability to develop eye diseases such as
glaucoma and cataracts.
Diabetic nephropathy It is a progressive reduction of the filter function of the kidney that, if untreated, can lead to renalfailure up to the need of dialysis and/or kidney transplant.
Diabetic neuropathy
It is one of the most frequent complications and according to the World Health Organization is
manifested at different levels in 50% of diabetics. It can cause loss of sensitivity, pain of varying
intensity, damage to limbs, requiring amputation in more severe cases, and increase in vascular
permeability. It may involve heart dysfunction of the eyes and stomach and is a major cause of male
impotence.
insulin signaling. The disease is usually classified into type 1
diabetes, type 2 diabetes, and other specific types including
gestational diabetes. Type 1 diabetes, also known as insulin-
dependent diabetes, represents about 5–10% of all cases of
diabetes. It is characterized by 𝛽-pancreatic cells destruction
that leads to absolute insulin deficiency. This failure to
produce insulin can be autoimmune-mediated or idiopathic.
Type 2 diabetes constitutes 90–95% of all diabetes cases
and results from insulin resistance, inadequate compensatory
insulin secretory response, or both. It is characterized by
reduced responsiveness of peripheral cells in the body to
insulin and, consequently, reduced ability to transfer glucose
out of the circulation [5]. Complications of diabetes can be
largely divided into microvascular and macrovascular com-
plications. The microvascular complications include diabetic
retinopathy, diabetic neuropathy, and diabetic nephropathy.
The macrovascular complications include cerebrovascular
disease, coronary heart disease, and peripheral vascular
disease (summarized in Table 1).
Elevated glucose levels result in an increased production
of reactive oxygen species (ROS) and inflammatory media-
tors strictly involved in vasculature dysfunction. The altered
system not only causes hypertension, ischemia, and/or al-
tered vascular permeability but also contributes to other
complications of diabetes [6, 7].
In the last decades, a big effort was put into finding
new therapeutic approaches to target either the full range
of diabetic complications or the damaged tissues/organs.
Although several classes of antidiabetic drugs are currently
available, achieving and maintaining long-term glycemic
control are often challenging and not sufficient alone, so a sig-
nificant need for novel antidiabetic drugs remains. It has been
discovered that neuropeptides and their analogues, activating
different signalling pathways through their receptors, are
emerging as new therapeutic options. Among these, one of
themost promising human peptides is the pituitary adenylate
cyclase-activating polypeptide (PACAP).This reviewoutlines
the knowledge accumulated over the past years on the role
of this neuropeptide in the major complications of diabetes,
particularly emphasizing its potential for new therapeutic
approaches.
3. PACAP, Receptors, and Functions
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PACAP38 chemical structure please refer to Figure 1) was
originally isolated from an ovine hypothalamus extract [8].
Two PACAP isoforms have been identified, a 38-amino-acid
form (PACAP38) and a C-terminally truncated 27-amino-
acid form (PACAP27). It belongs to the secretine, glucagon,
and peptide histidine-isoleucine (PHI) superfamily and binds
to an overlapping group of receptors. PACAP receptors
are G protein-coupled receptors and can be classified into
two main groups, PAC1 and VPAC (including VPAC1 and
VPAC2 subtypes), both of which activate adenylate cyclase
with consequent stimulation of cAMP production and IP
accumulation [9, 10]. In distinct cell types, PACAP is able
to trigger different pathways, depending on which receptor
splice variants are expressed, peptide concentration being
used, and other biological factors. Among PACAP functions,
the one that mostly emerges is its strong cytoprotective
role, promoting survival in many types of neuronal and
nonneuronal cells and tissues, including lymphocytes, chon-
drocytes, endothelial cells, Schwann cells, liver, lung, and
ovary [11–17]. In vitro and in vivo studies have shown that
the peptide acts through the PAC1 receptors to stimulate
various downstream executors of the protein kinase A and
C (PKA and PKC) pathways [18–21]. It also activates ion
channels, 𝛽-arrestin signalling, and mitogen-activated pro-
tein (MAP) kinase in some tissues [22, 23]. PACAP and
its receptors have been detected in multiple organs, with
the highest levels in endocrine glands and in the central
nervous system. Lower expression has been identified in
gastrointestinal, respiratory, cardiovascular, and urogenital
systems [24, 25]. Ultrastructural studies have also revealed
that PACAP immunoreactivity is mainly localized near








































































































































































Figure 1: 2D chemical structure of full-length PACAP38 (CID 44566111). The chemical structure was retrieved using the publicly available
PubChem database source, accessible at https://pubchem.ncbi.nlm.nih.gov/compound/44566111#.
the plasma membrane, in the rough endoplasmic reticulum,
in the Golgi’s apparatus, and in the cytoplasmic matrix [26–
28]. Such a broad distribution of PACAP in several tis-
sues/organs, together with the variety of signalling pathways
shown to be activated, poses the peptide in a position suitable
to be considered a key drug candidate with the potential to
ameliorate a wide spectrum of disorders, including diabetes
and its major complications.
4. PACAP and PAC1 Receptors
Distribution in the Retina
PACAP and its high-affinity receptor PAC1 are broadly dis-
tributed in a number of organs/systems. Of interest, different
studies using rodents have shown that both PACAP and
PAC1 immunoreactivity (IR) sites are also detectable in the
retina and the nervous tunica of the eye, both known to
be highly sensitive to long-lasting glucose insult. Indeed,
immunohistochemistry studies have shown that PACAP-like
IR is evident in a population of sensory neurons in the rat
uvea [29, 30] and in trigeminal ganglion cells [31]. PACAP-
IR is also localized at high densities in nonretinal parts of the
eye, such as the iris sphincter and the ciliary body [31, 32].
Topographically, specific cell populations were found to be
positive for PACAP in retinal tissue samples. In particular,
PACAP-positive nerve fibers have been detected in the nerve
fiber layer (NFL), the ganglion cell layer (GCL), and the
inner plexiform layer (IPL). PACAP-IR was found to be
positive in neuronal cell bodies of amacrine and horizontal
cells localized in the inner nuclear layer (INL). However,
no PACAP-IR has ever been established in rods and cones
(photoreceptors) in the outer nuclear layer (ONL) or in
neighboring retinal pigmented epithelium [27, 33, 34].
In the IPL, PACAP+ amacrine cell processes make synap-
tic contacts with retinal ganglion cell (RGC) terminals, as well
as amacrine and bipolar cell processes. PACAP+ amacrine
cells also establish synaptic contacts with each other. PACAP+
axon terminals establish synapses with ganglion cells, bipolar
cells, amacrine cells, and horizontal cells in the GCL, NFL,
and IPL.
Studies concerning PAC1 receptor distribution have indi-
cated that binding sites for PACAP and VIP, positively
coupled to adenylate cyclase, are expressed in the retina
of different mammalian species [18]. PAC1-IR in the retina
seems to bemainly detectable in the cell bodies and processes
of ganglionic and amacrine cells but not in photoreceptors.
At the subcellular level, PAC1 receptors are localized at the
plasma membrane, in the rough endoplasmic reticulum, and
in the cytoplasmic matrix of RGCs and amacrine cells in
the INL. Of note, it has been shown that PAC1 receptor
localization not always matches with peptide expression. For
instance, in the rat brain, PAC1-IR has been found at high
levels in the olfactory bulb, hippocampus, and cerebellar
cortex, where only few or no PACAP-containing neurons
are identified. However, this may be due to the difficulties
associated with detecting antigens in retinal tissue or in
nervous tissue in general. However, although it has not been
detected in Müller cells in vivo, PAC1+ has been shown in rat
primary cultures of Müller cells [35]. For a comprehensive
summary depicting PACAP and PAC1 receptor localization
to specific cell populations in rodent retina, please refer to
Figure 2.
5. PACAP and Diabetic Endothelial
Dysfunction
Diabetes is characterized by a high risk of developing chronic
complications, with micro- and macrovascular impairments
in multiple organs. Today it is well established that increased





























Figure 2: Representative schematic illustration showing PACAP
and PAC1 distribution in rodent retina. Immunohistochemical
studies have shown that PACAP immunoreactivity (IR) is detectable
in nerve fibers (neurites) originating from retinal ganglionic cells as
well as in neuronal cell bodies of amacrine and horizontal cells in the
inner nuclear layer. No evidence of PACAP-IR has been provided
in photoreceptors in the outer nuclear layer (ONL) or in the retinal
pigmented epithelium (RPE) [22, 28, 29].
oxidative stress impairs endothelial function and it is thought
to mediate vascular disease.
Vascular function depends upon the balance of oxidant
and antioxidant mechanisms. During diabetes, an unbalance
between anti-inflammatory and antithrombotic homeostasis
in favor of proinflammatory and thrombogenic elements is
evident. Heightened oxidative stress and altered expression of
a variety of genes related to atherogenesis and angiogenesis
have also been described in the vasculature exposed to
elevated levels of glucose [6, 7, 36–39].
In addition, trophic factor alterations associated with
early and late stages of diabetes seem to aggravate hyper-
glycemia-induced proliferative response, resulting in in-
creased basement membrane thickening and aberrantly
regulated vasculogenesis. On the other hand, molecules like
PACAP, though being commonly recognized as trophic
factors, have demonstrated to also possess opposite biological
roles in the vasculature system, most likely depending on the
surrounding microenvironment or other coexisting factors,
and have been therefore defined as “nonclassic endogenous
regulators of angiogenesis” [39]. To support this concept,
studies from independent laboratories, including ours, have
succeeded to demonstrate that PACAP exerts a rate-limiting
effect on cell proliferation under specific pathological
conditions replicated in vitro, such as longstanding high
glucose exposure in murine microvascular endothelial cells
[40] or in aortic smooth muscle cells [41], acting oppositely
to the canonical trophic roles. However, the seeming duality
of PACAP acting either as a “classic” or “nonclassic” trophic
factor molecule should be considered with care.Themajority
of growth-promoting functions associated with PACAP
are complex and context specific, suggesting that the way
PACAP responds to “stimuli” depends both on the cell/tissue
types, local peptide concentration, bioavailability, and
alternative splicing mechanisms but depends also on the
nature of the insult itself. In our laboratory, we showed
that PACAP was apparently devoid of biological activity
on endothelial cells up to 7 days of exposure, whereas the
peptide elicited an antiproliferative response after chronic
exposure (up to 15 days) to high glucose (25mM) in the
H5V murine microvascular endothelial cell line used [42].
In that same study, we also observed that PACAP and its
structurally related homolog vasoactive intestinal peptide
(VIP) were unable to induce proliferative activity on their
own or to show intrinsic effects on cell viability in these cell
lines, although they prevented glucose-induced cell death,
possibly by dampening ROS-induced oxidative stress, as
indicated by other researchers [43]. It is thus plausible that
PACAP may play a dual growth-inhibitory and protective
role to arrest the aberrantly activated neovascularization
and prevent ROS-mediated apoptosis under hyperglycemic
conditions (a schematic representation is depicted in
Figure 3).
The importance of PACAP in relationship to circulatory
dysfunction caused by long-standing diabetes does not seem
to be solely limited to restoring microvasculature, as the
combined vasodilatory effects together with the growth-
inhbitory functions of the peptide can be extended to the cir-
culatory system in general. In particular, the PACAPhomolog
VIP has captured scientific interest because of its growth
inhibitory properties on smooth muscle cells [44], inferring
on its potential effects on diabetes-induced hypertension.
It was later discovered that, similarly to VIP, a comparable
effect can also be achieved using PACAP, since the main
receptor involved is the PACAP/VIP equal affinity receptor
VPAC2 [41]. Consistent with the hypotensive effect mediated
by VPAC2 receptors, at least a study has demonstrated that
PACAP, synthesized in the adrenal medulla, is able to activate
VPAC1/VPAC2 receptors in the zona glomerulosa of the
adrenal gland, ultimately promoting the systemic release
of aldosterone, an endogenous hypotensive hormone [45].
However, other important functions that may be transferred
to the circulatory system have been observed, in particular
concerning VPAC2 receptor function. Of note, evidence has
been provided regarding the potential lipolytic effects exerted
by PACAP/VIP-VPAC2 axis in cultured adipocytes [46]. Such
activity may have positive repercussions for the search of new
strategies to counteract atherogenesis, especially in chronic
diabetic patients.
Based on the in vitro and in vivo evidences discussed
here, it appears that PACAP, by recruiting different recep-
tors in a cell type-dependent fashion, activates a series of
physiological/compensatory responses finalized to reestab-
lish vascular homeostasis. However, further investigations
might still be needed to better define the specific actions
mediated by each binding receptor, as this will set the
stage to develop new highly selective PACAP analogues or
receptor agonists encompassing therapeutical activity for
the treatment of vascular complications associated with
diabetes.
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Figure 3: Proposed model depicting the ameliorative role of PACAP in hyperglycemia-induced endothelial dysfunction: potential
involvement of smooth muscle cells through a paracrine mechanism. One of the most devastating complications of persistent hyperglycemia
is micro- and macroangiopathy that may determine abnormal vasculogenesis. However, the exact pathogenetic mechanisms are still not well
understood. In the proposed scenario, longstanding high glucose levels in the blood stream cause both mechanical (shear stress) or oxidative
injury (↑ ROS production) to endothelial cells, whose in turn react by triggering local inflammatory responses, sustained PKC activation,
and aberrant angiogenesis (↑ endothelial cell proliferation). PACAP seems to play a homeostatic role in this process. Once released by the
neighboring smooth muscle cells (SMCs) it binds to PAC1 receptors expressed by both endothelial cells and SMCs, thereby activating a
cAMP-driven signalling cascade that inhibits glucose-induced proliferation of both cell populations and ROS production and dampens PKC
function as well as local release of proinflammatory cytokines by infiltrating macrophages.
6. Trophic Effects of PACAP on
Pancreatic Islets
A hallmark of both types I and II diabetes is the progressive
𝛽-cell insufficiency in the pancreas, which results in defects in
insulin secretion and hyperglycemia [47, 48]. Pancreatic islet
cell apoptosis, induced by various factors such as oxidative
stress, inflammation, and toxicity of chronic high blood sugar,
results inevitably in a decline of 𝛽-cell mass and function in
diabetic patients and causes diabetic complications, including
diabetic nephropathy, neuropathy, and retinopathy [49, 50].
About two decades ago, PACAP was identified as a novel islet
substance that is synthesized and released by pancreatic 𝛽-
cells. PACAP protein was colocalized to secretory vesicles of
insulin and glucagon-containing cells in human and rodent
pancreases [51]. In situ hybridization studies have also shown
that both PAC1 and VPAC2 receptors are expressed in the
𝛽 cells, being the predominant PACAP binding receptors
in these cells, while VPAC1 receptors were detected only in
vessels surrounding the islets [22, 52]. Accumulating in vivo
and in vitro studies have shown that PACAP, in an autocrine
and/or paracrine manner, produces trophic effects on 𝛽-
cells. It stimulates the main endocrine pancreatic function
(insulin production and release), preserves 𝛽-cell responses
to glucose, and regulates both proliferation and cell viability
[53–57]. Studies attempting to establish the exact role of each
of the receptors in mediating beneficial activities on 𝛽-cell
population have taken advantage on genetically engineered
mice with either a targeted deletion of the PAC1 receptor
gene (PAC1−/−) or of the VPAC2 receptor gene (VPAC2−/−).
Either knockout animal model displays reduced insulin
response to both gastric and, to a lesser extent, intravenous
glucose administration. These mice also display impaired
glucose elimination. PAC1 deletion is also associated with
a robust reduction of glucose-stimulated insulin secretion,
suggesting that PACAP through PAC1 receptors might also
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play a role in modulating the insulin secretory response to
glucose itself. Regarding VPAC2−/− models, although these
mice develop normally, they exhibit increased metabolic rate
and increased insulin sensitivity, accompanied by reduced
body weight due to reduced fat mass. As for PAC1 receptors,
these observations suggest that VPAC2 receptors might as
well be necessary for physiological insulin secretion [58].
However, despite the common insulinotrophic responses
mediated by the two receptors, studies focusing on the diverse
potential actions exerted by PACAP are still warranted,
since a variety of different intracellular signalling molecules
(e.g., cAMP, PKA, ion channels, and MAP kinases) may be
differently involved and act in concert in a context-dependent
manner to produce variable effects on pancreatic islets during
diabetes progression.
7. PACAP Protection in Diabetic Retinopathy
Diabetic retinopathy (DR) is one of the most significant and
disabling chronic complications of diabetes mellitus [59]. DR
can be generally divided into two clinical stages: nonprolif-
erative and proliferative diabetic retinopathy (PDR). During
nonproliferative DR, abnormal permeability and/or nonper-
fusion of capillaries lead to the formation of microaneurysms
and leakage of fluid and solutes into the surrounding reti-
nal tissue which accumulates around the macula, causing
diabetic macular oedema (DMO). As DR severity increases,
vascular abnormalities (occlusion of retinal capillaries; retinal
ischemia) and aberrant neovascularization, a process by
which new blood vessels proliferate on the surface of the
retina, defining PDR, occur [60]. The tight control of blood
glucose levels and blood pressure are essential in preventing
or arresting their development. However, these therapeutic
objectives are difficult to achieve, even with strict glycemic
control, and as a consequence PDR and DMO still appear
in a high percentage during the evolution of the disease in
patients with both type I and type 2 diabetes [61]. DRhas been
considered, for many decades, as a microangiopathy disease
of the retina with key clinical features, vascular leakage,
and preretinal neovascularization, resulting from breakdown
of the blood retinal barrier (BRB) [62]. However, there is
a mounting evidence to suggest that the pathogenesis of
DR may also comprise neuroinflammatory and neuropathic
processes, which contribute to visual impairment [63]. Loss
of neuroretinal adaptation to the diabetic metabolic envi-
ronment and neural apoptosis may occur in DR prior to
any clinically detectable microvasculopathy, in both human
and animal models [64]. In this scenario, hyperglycemia is
considered the main culprit for both neural and vascular
compromising. The numerous metabolic pathways triggered
by hyperglycemia such as the polyol pathway, the hexosamine
pathway, the DAG-PKC pathway, advanced glycation end-
products beside extracellular glutamate accumulation, oxida-
tive stress, and reduction of neuroprotective factors syn-
thesized by the retina lead to neuronal apoptosis and glial
dysfunction, hallmarks of retinal neurodegeneration and
BRB breakdown, vasoregression, and altered microvascular
system [65]. The presence of neuropeptides in the human
retina has mostly been studied by immunohistochemical
and chromatographic assays. Neuropeptides are produced
from both neural and nonneural cells, and some peptides
can also be produced by other extraretinal cell sources. It
has now become clear that the neuropeptides described in
the retina can be divided in two categories: peptides that
promote the development of DR symptoms and others that
are able to prevent, delay, or eliminate them. The retinal
balance between the neurotoxic and neuroprotective events
is crucial to determine neuronal cell fate in the diabetic retina
[66]. It is well documented that PACAP and its receptors are
expressed in the retina [18, 27, 28] and increasing evidence
suggests the retinal protective role of the peptide in different
retinal pathologies. A recent study by our research group has
shown that, in retina of diabetic rats, an initial upregulation
of both PACAP and related receptors preceding morpho-
logical evidence of cell death is evident [67]. In that same
study, we also showed that PACAP intravitreal treatment
downregulated the expression of proapoptotic genes along
with other evidences of its protective effects, suggesting
an active role for this peptide in counteracting some of
the pathogenetic events of DR by different mechanisms,
including the apoptotic machinery [68]. Additional studies
have confirmed that intraocular injection of PACAP exerts
protective effects by increasing anti- and decreasing proapop-
totic factors. Indeed, it has been shown that PACAP injections
markedly attenuated diabetic retinal injury by increasing the
levels of the antiapoptotic p-Akt, pERK1, p-ERK2, PKC, and
Bcl-2 signalling, while decreasing the levels of the proapop-
totic p-p38MAPK pathway (Figure 4). PACAP also protects
ganglion cells and dopaminergic amacrine cells degeneration
in experimental diabetes [69, 70]. PACAP emerges as a
strong antiapoptotic factor that exerts its effect by acting
at different levels of the apoptotic cascade [70, 71]. Further,
the broad distribution of the peptide, along with that of its
high affinity receptor PAC1, raises the question on whether
PACAP-PAC1 axis might also play protective functions in the
retina. Consistent with previous evidences from our research
group [67], Szabadfi and coworkers [68, 69] have shown that
retinal PAC1 receptors are the main receptors to mediate
the ameliorative effects on the structural changes caused
by streptozotocin in a model of early diabetic retinopathy.
It appears though that PACAP acting through PAC1 may
indeed trigger protective mechanisms in the retina during
diabetic insults. Consistent with such protective function,
its potential therapeutic role has also been demonstrated in
a model in vitro of DMO, hence showing that PACAP is
able to also prevent the disruption of the BRB, mainly by
modulating the expression of important tight junctions such
as zona occludens-1 (ZO-1) and claudin-1, both essential for
the proper functionality of the retinal barrier during diabetes
[72].
8. PACAP in Diabetic Nephropathy
Alterations in renal function and structure are found even
at the onset of diabetes mellitus. Diabetic nephropathy is
characterized by initial proteinuria followed by a decline
in glomerular filtration rate and ultimate progression to
uraemia. Diabetic nephropathy is the leading cause of
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Figure 4: Schematic diagram showing the main prosurvival/antiapoptotic intracellular pathways activated by PACAP. As apparent from the
diagram, the intrinsic apoptotic cascade represents one of themain targets of PACAP to protect cells from death. cAMP, cyclic 3󸀠,5󸀠 adenosine
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end-stage renal failure and about 30–40% of patients need
renal transplantation [73]. The main clinical features that
frequently precede diabetic nephropathy are hypertension
and poor glycemic control. Key factors that are involved in
diabetic kidney damage are oxidative stress, overproduction
of advanced glycation end products (AGE), apoptosis, and
inflammation due to the local release of proinflammatory
cytokines [74]. Despite the well-established activities of
the peptide in many other diabetes complications, the
action of PACAP in the kidney of diabetic patients has
captured scientific interest only in the past two years.
Since the pleiotropic peptide is known to exert anti-
inflammatory, antiapoptotic, and antioxidant effects, it
appeared reasonable to think that it could be a suitable
candidate to also prevent the development or delay the
progression of DN. A recent publication by Banki and
coworkers identified new molecular mechanisms underlying
PACAP nephroprotective properties, including the ability to
reduce fibrotic markers, like collagen IV and TGF-𝛽1 in the
kidney, or hampering the proapoptotic p38 MAPK pathway
[75]. Indeed, other sparse pieces of evidence inferring
on the potential beneficial effects of PACAP have been
previously described in the kidney using in vitro models,
such as vasodilation and renin secretion [76] and protective
effects against hydrogen peroxide-induced oxidative stress
[72]. In vivo models of diabetic nephropathy have also
proven the protective role of PACAP in this pathological
condition. Its ameliorative effects against high glucose-driven
kidney impairment seem to be in part due to inhibition of
apoptotic, fibrotic, and oxidative pathways, paralleled by
anti-inflammatory properties of the peptide [75, 77].
Although promising, these investigations may be considered
as proof-of-concept studies and will require more in-
depth studies to really prove the potential therapeutic
validity of PACAP against this specific diabetes-associated
complication.
9. Neuropathy and Future PACAP
Application?
A further severe complication in most cases secondary to
angiopathy is diabetic neuropathy, which affects the periph-
eral nervous system. Over half of all patients affected by
diabetes develop some form of neuropathy, resulting in
sensory loss, pain, and autonomic dysfunction. These mani-
festations of neuropathy can severely reduce a patient’s quality
of life. As for the previous complications discussed above,
duration of diabetes and glycemic control are important
risk factors for neuropathy in both patients with type 1 and
type 2 diabetes [78]. Actually, no therapy is approved by
regulatory bodies in Europe and theUnited States for diabetic
degenerative neuropathy. The only strategy adopted is the
maintenance of normoglycemia, but current treatments for
pain management are not effective and/or do not target the
causes of diabetes-induced pain. The lack of therapies largely
reflects the absence of suitable animal models to study the
exact causes of neuropathy [79]. In this scenario, PACAP
could be considered a good candidate target considering its
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numerous beneficial properties. It can circulate in the brain
and to some extent cross the blood brain barrier. In particular,
the shorter form (PACAP 27) is transported into the brain by
transmembrane diffusion, a nonsaturable mechanism, while
the uptake of PACAP 38 into the brain occurs through a sat-
urable mechanism. However, to date no significant data has
been produced in relationship to this diabetic complication.
A plausible reason to explain such an apparent lack of interest
on the use of PACAP to treat or prevent diabetic neuropathy
could be related to its relatively low bioavailability in the
brain. In fact, when administered systemically, native PACAP
is rapidly hydrolyzed by the ubiquitous enzyme dipeptidyl-
peptidase IV (DPP IV) to form PACAP (3–38) or PACAP
(5–38), which are two shorter forms of the peptide with an
antagonist activity on PAC1 receptors in most cases [80]. The
degradation by DPP IV in the blood circulation also results
in the poor metabolic stability with short half-life between 2
and 10min after PACAP is injected into mice or human [81].
N-terminal truncation of PACAP by removal of the first five
amino acids results in a potent PAC1 antagonist that retains
the ability to bind PACAP binding sites, does not stimulate
adenylate cyclase, and inhibits the ability of PACAP to
stimulate adenylate cyclase. With this in mind, the beneficial
results of PACAP treatment may be present only when the
peptide is administered locally, and this is a great limitation
to its clinical use. Current efforts by research laboratories and
biotechnologies are now being put to develop a more stable
form of the peptide that still retains its ability to cross the
blood brain barrier and reach the central or peripheral ner-
vous system.However, at least a research group has succeeded
in developing a novel cyclopeptide from the cyclization of
PACAP (1–5) that possesses potent activity towards PAC1
and is able to attenuate experimentally-induced diabetes and
ganglionic cell death [82, 83], suggesting that advances have
been made to overcome the problems associated with poor
peptide availability. An alternative objective being pursued
is to increase the average half-life of the peptide once sys-
temically injected. The strategy could be by blocking DPP IV
enzymatic activity on PACAP through the coadministration
of a specific inhibitory agent. Interestingly, metformin, an
oral agent commonly prescribed to treat type 2 diabetes
involved in the reduction of hepatic glucose production
and/or insulin resistance, has shown to also decrease plasma
DPP IV activity, limiting the inactivation of exogenously
administered peptides [84]. In this regard, Ahrén andHughes
(2005) [85] have elegantly demonstrated that another DDP
IV inhibitor, namely, valine-pyrrolidide, when administered
through gastric gavage, increases insulin response to PACAP
and other substrates of the enzyme, opening newperspectives
on the potential clinical validity of the peptide.
10. Conclusions
Thepresent review summarizes the findings on the neuropro-
tective potential of PACAP in major diabetes complications.
Based on these data, PACAP emerges as a powerful and
promising candidate in the treatment of those pathological
conditions associated with long-lasting diabetes. From the
present review it arises that diabetic complications are the
main consequence of significant changes in vascular structure
and function, along with other metabolic alterations. PACAP
appears to be able to effectively counteract and/or prevent the
majority of these changes, making it a potentially valuable
candidate to treat diabetes complication. Unfortunately, a
major hurdle that has significantly limited PACAP therapeu-
tic use in T2D-related injuries depends on the rapid hydrol-
ysis of the peptide occurring when injected systemically.
Future efforts are therefore necessary to develop a peptide
analogue which is more stable, can easily cross human
biological barriers (i.e., blood and retinal brain barrier) to
bind its receptors in affected organs/systems, and possesses
adequate pharmacokinetics. Alternatively, other routes could
be to take advantage of new generation viruses for PACAP
gene delivery to treat this still unmet medical need, but
further studies in this direction are yet to be carried out to
exclude any possible associated risk.
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[46] L. Åkesson, B. Ahrén, G. Edgren, and E. Degerman, “VPAC2-
R mediates the lipolytic effects of pituitary adenylate cyclase-
activating polypeptide/vasoactive intestinal polypeptide in pri-
mary rat adipocytes,”Endocrinology, vol. 146, no. 2, pp. 744–750,
2005.
[47] C. J. Rhodes, “Type 2 diabetes—a matter of 𝛽-cell life and
death?” Science, vol. 307, no. 5708, pp. 380–384, 2005.
[48] H. E. Thomas and T. J. Biden, “Bad news for 𝛽-cell apoptosis,”
Diabetes, vol. 58, no. 8, pp. 1725–1727, 2009.
[49] D. Mathis, L. Vence, and C. Benoist, “𝛽-cell death during pro-
gression to diabetes,” Nature, vol. 414, no. 6865, pp. 792–798,
2001.
[50] R. P. Robertson and J. S. Harmon, “Diabetes, glucose toxicity,
and oxidative stress: a case of double jeopardy for the pancreatic
islet 𝛽 cell,” Free Radical Biology and Medicine, vol. 41, no. 2, pp.
177–184, 2006.
[51] G. M. Portela-Gomes, A. Lukinius, O. Ljungberg, S. Efendic,
B. Ahrén, and S. M. Abdel-Halim, “PACAP is expressed in
secretory granules of insulin and glucagon cells in human
and rodent pancreas: evidence for generation of cAMP com-
partments uncoupled from hormone release in diabetic islets,”
Regulatory Peptides, vol. 113, no. 1–3, pp. 31–39, 2003.
[52] N. Inagaki, H. Yoshida, M. Mizuta et al., “Cloning and func-
tional characterization of a third pituitary adenylate cyclase-
activating polypeptide receptor subtype expressed in insulin-
secreting cells,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 91, no. 7, pp. 2679–2683,
1994.
[53] T. Yada, M. Sakurada, H. Ishihara et al., “Pituitary adenylate
cyclase-activating polypeptide (PACAP) is an islet substance
serving as an intra-islet amplifier of glucose-induced insulin
secretion in rats,” Journal of Physiology, vol. 505, no. 2, pp. 319–
328, 1997.
[54] K. Yamamoto, H. Hashimoto, S. Tomimoto et al., “Overexpres-
sion of PACAP in transgenicmouse pancreatic𝛽-cells enhances
insulin secretion and ameliorates streptozotocin-induced dia-
betes,” Diabetes, vol. 52, no. 5, pp. 1155–1162, 2003.
[55] S. Onoue, J. Hanato, and S. Yamada, “Pituitary adenylate
cyclase-activating polypeptide attenuates streptozotocin-in-
duced apoptotic death of RIN-m5F cells through regulation of
Bcl-2 family protein mRNA expression,”The FEBS Journal, vol.
275, no. 22, pp. 5542–5551, 2008.
[56] D. Vaudry, A. Falluel-Morel, S. Bourgault et al., “Pituitary
adenylate cyclase-activating polypeptide and its receptors: 20
years after the discovery,” Pharmacological Reviews, vol. 61, no.
3, pp. 283–357, 2009.
[57] Y. Sakurai, N. Shintani, A. Hayata, H. Hashimoto, and A. Baba,
“Trophic effects of PACAP on pancreatic islets: a mini-review,”
Journal of Molecular Neuroscience, vol. 43, no. 1, pp. 3–7, 2011.
[58] B. Ahrén, “Role of pituitary adenylate cyclase-activating
polypeptide in the pancreatic endocrine system,” Annals of the
New York Academy of Sciences, vol. 1144, pp. 28–35, 2008.
[59] N. G. Congdon, D. S. Friedman, and T. Lietman, “Important
causes of visual impairment in the world today,” Journal of the
American Medical Association, vol. 290, no. 15, pp. 2057–2060,
2003.
[60] R. Williams, M. Airey, H. Baxter, J. Forrester, T. Kennedy-
Martin, and A. Girach, “Epidemiology of diabetic retinopathy
and macular oedema: a systematic review,” Eye, vol. 18, no. 10,
pp. 963–983, 2004.
[61] Q. Mohamed, M. C. Gillies, and T. Y. Wong, “Management
of diabetic retinopathy: a systematic review,” Journal of the
AmericanMedical Association, vol. 298, no. 8, pp. 902–916, 2007.
[62] P. Kolár, “Patophysiology of diabetic retinopathy,” Vnitřnı́
lékařstvı́, vol. 59, no. 3, pp. 173–176, 2013.
[63] D. A. Antonetti, A. J. Barber, S. K. Bronson et al., “Diabetic
retinopathy: seeing beyond glucose-inducedmicrovascular dis-
ease,” Diabetes, vol. 55, no. 9, pp. 2401–2411, 2006.
[64] X. Zhang, N. Wang, G. R. Barile, S. Bao, and M. Gillies, “Dia-
betic retinopathy: neuron protection as a therapeutic target,”
The International Journal of Biochemistry & Cell Biology, vol. 45,
no. 7, pp. 1525–1529, 2013.
[65] M. Brownlee, “Biochemistry and molecular cell biology of
diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820,
2001.
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